News coverage about Caladrius Biosciences (NASDAQ:CLBS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.6467935159371 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of analysts have weighed in on the company. HC Wainwright set a $7.00 price target on Caladrius Biosciences and gave the company a “buy” rating in a research note on Friday, January 19th. Zacks Investment Research cut Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th.
Caladrius Biosciences (NASDAQ:CLBS) traded down $0.02 during trading on Monday, reaching $4.28. The company’s stock had a trading volume of 10,565 shares, compared to its average volume of 54,346. Caladrius Biosciences has a one year low of $2.63 and a one year high of $7.79. The firm has a market capitalization of $40.72, a PE ratio of -2.07 and a beta of 1.59.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.